- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Placebo, JNJ-31001074
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 21
- States / cities
- Irvine, California • Lafayette, California • San Francisco, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 169
matching trials from the live ClinicalTrials.gov search.
- Conditions
- ADHD
- Interventions
- NRCT-101-SR, Placebo
- Drug
- Lead sponsor
- Neurocentria, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Active transcranial photobiomodulation, Sham transcranial photobiomodulation
- Device
- Lead sponsor
- Francisco Gonzalez-Lima, PhD
- Other
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine Hydrochloride, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 20
- States / cities
- Irvine, California • Gainesville, Florida • Tampa, Florida + 17 more
- Conditions
- ADHD
- Interventions
- Meditation/Relaxation Response Training
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Placebo, Ritalin LA 20 mg, Ritalin LA 30 mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 725 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 16 more
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Lisdexamfetamine Dimesylate 40 MG, Placebo
- Drug
- Lead sponsor
- Gregory Fabiano
- Other
- Eligibility
- 16 Years to 25 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
- Interventions
- Centanafadine SR, Placebo
- Drug · Other
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- TC-5619-238 5mg, TC-5619-238 25mg, Placebo
- Drug
- Lead sponsor
- Targacept Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • National City, California • Colorado Springs, Colorado + 9 more
- Conditions
- ADHD
- Interventions
- TC-5619-238, Placebo
- Drug
- Lead sponsor
- Targacept Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 16
- States / cities
- Bradenton, Florida • Jacksonville, Florida • Lauderhill, Florida + 13 more
- Conditions
- ADHD
- Interventions
- Dance Exergaming, Stationary Cycling, Music Listening
- Behavioral
- Lead sponsor
- Virginia Polytechnic Institute and State University
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Blacksburg, Virginia
- Conditions
- Cerebrovascular Accident, Transient Ischemic Attack, ADHD
- Interventions
- atomoxetine, Stimulants, No intervention (general population)
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- ADHD
- Interventions
- lisdexamfetamine
- Drug
- Lead sponsor
- Florida International University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline, Placebo
- Drug · Other
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 48 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- NS2359, Placebo
- Drug
- Lead sponsor
- NeuroSearch A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- UC-A, UC-N
- Device
- Lead sponsor
- Think Now Incorporated
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 2
- States / cities
- Berkeley, California • Los Angeles, California
- Conditions
- ADHD
- Interventions
- memantine hydrochloride
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Attention Deficit Disorder, Attention Deficit Hyerpactivity Disorder
- Interventions
- Highly unsaturated omega-3 fatty acids
- Other
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- ADHD
- Interventions
- Drug: PRC-063, PRC-063
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 30
- States / cities
- Los Angeles, California • National City, California • Newport Beach, California + 25 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d, JNJ-31001074 10 mg/d
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 35
- States / cities
- Little Rock, Arkansas • Lafayette, California • Los Alamitos, California + 32 more
- Conditions
- Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
- Interventions
- NRP104
- Drug
- Lead sponsor
- New River Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- OPC-64005, Atomoxetine, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 26
- States / cities
- Beverly Hills, California • Garden Grove, California • San Diego, California + 20 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Mindfulness Awareness Practices for ADHD (adapted), Services-As-Usual
- Behavioral
- Lead sponsor
- University of Alabama, Tuscaloosa
- Other
- Eligibility
- 17 Years to 25 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Tuscaloosa, Alabama • Spartanburg, South Carolina
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Oxytocin nasal spray, Placebo nasal spray
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts